InvestSMART

Percheron Therapeutics Limited (ASX: PER) - Announcements

- Current share price for PER : $0.004

ASX company news and announcements for Percheron Therapeutics Limited (PER) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Percheron Therapeutics Limited (PER) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Percheron Therapeutics Limited (PER), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Percheron Therapeutics Limited (PER)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Notice under S708A 25 Oct 2024 8:23AM $0.079 $0.004 fallen by 94.94%
$7 Application for quotation of securities - PER 24 Oct 2024 8:22AM $0.081 $0.004 fallen by 95.06%
$7 Proposed issue of securities - PER 23 Oct 2024 9:42AM $0.084 $0.004 fallen by 95.24%
$7 Percheron to launch Share Purchase Plan 23 Oct 2024 9:36AM $0.084 $0.004 fallen by 95.24%
$7 Update - Proposed issue of securities - PER 23 Oct 2024 9:14AM $0.084 $0.004 fallen by 95.24%
$7 Percheron Holds International Advisory Boards 21 Oct 2024 9:07AM $0.089 $0.004 fallen by 95.51%
$7 Addendum to 2024 Notice of Annual General Meeting 18 Oct 2024 1:22PM $0.089 $0.004 fallen by 95.51%
$7 2024 Notice of Annual General Meeting 18 Oct 2024 10:35AM $0.088 $0.004 fallen by 95.45%
$7 Proposed issue of securities - PER 18 Oct 2024 9:24AM $0.135 $0.004 fallen by 97.04%
$7 Proposed issue of securities - PER 18 Oct 2024 9:24AM $0.135 $0.004 fallen by 97.04%
$7 $13.0 million Institutional Placement 18 Oct 2024 9:23AM $0.135 $0.004 fallen by 97.04%
$7 Trading Halt 16 Oct 2024 8:42AM $0.135 $0.004 fallen by 97.04%
$7 Percheron Receives $2.35 million R&D Tax Incentive Rebate 8 Oct 2024 9:37AM $0.105 $0.004 fallen by 96.19%
$7 Change of Company Auditor 1 Oct 2024 8:24AM $0.105 $0.004 fallen by 96.19%
$7 Completion of avicursen (ATL1102) toxicology study 30 Sep 2024 9:07AM $0.100 $0.004 fallen by 96%
$7 Percheron Therapeutics Limited Corporate Presentation 4 Sep 2024 8:41AM $0.083 $0.004 fallen by 95.18%
$7 ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy 3 Sep 2024 9:47AM $0.085 $0.004 fallen by 95.29%
$7 Notice of date of AGM and other relevant dates 29 Aug 2024 3:18PM $0.081 $0.004 fallen by 95.06%
$7 Appendix 4G and Corporate Governance Statement 29 Aug 2024 3:14PM $0.081 $0.004 fallen by 95.06%
$7 Appendix 4E and Annual Report 29 Aug 2024 3:11PM $0.081 $0.004 fallen by 95.06%
$7 Quarterly Activities Report and Appendix 4C 31 Jul 2024 8:10AM $0.070 $0.004 fallen by 94.29%
$7 Notification regarding unquoted securities - PER 4 Jul 2024 4:42PM n/a $0.004 n/a
$7 Deborah Ambrosini appointed as CFO & Company Secretary 17 Jun 2024 9:04AM $0.092 $0.004 fallen by 95.65%
$7 Percheron appoints Dr Cathryn Clary as Chief Medical Advisor 3 Jun 2024 8:31AM $0.081 $0.004 fallen by 95.06%
$7 Percheron to present at 2024 BIO International Convention 31 May 2024 8:32AM $0.074 $0.004 fallen by 94.59%

151 - 175 of 204 results

Page 7 of 9

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.